Young HCL patients at first relapse after receiving cladribine
| Number | 48 |
| Age | |
| Median (y) | 38 |
| Range | 31-55 |
| Sex | |
| Male | 36 |
| Female | 12 |
| Disease duration before cladribine | |
| Median (mo) | 15 |
| Range | 0-668 |
| Treatment before cladribine | |
| None | 29 |
| Splenectomy alone | 3 |
| Interferon alone | 6 |
| Splenectomy, interferon | 6 |
| Splenectomy, interferon, 2′-deoxycoformycin | 2 |
| Chlorambucil, splenectomy | 1 |
| Other regimens | 1 |
| First response to cladribine | |
| CR | 37 |
| PR | 8 |
| Unknown | 3 |
| Peripheral blood hematologic parameters at first relapse | |
| Absolute neutrophil count (×109/L) | |
| Median (range) | 1.4 (0.6-6.0) |
| Hemoglobin level (g/dL) | |
| Median (range) | 14.2 (8.7-17.5) |
| Platelets (×109/L) | |
| Median (range) | 135 (4-403) |
| Duration to first relapse from cladribine therapy | |
| Median (mo) | 54 |
| Range | 7-246 |
| Treatment at relapse | |
| None | 11 |
| Cladribine | 31 |
| Rituximab | 5 |
| Cladribine + rituximab | 1 |
| Response to second course of cladribine (31 patients) | |
| CR | 12 |
| PR | 6 |
| CHR | 8 |
| No response | 1 |
| Unknown | 4 |
| Number | 48 |
| Age | |
| Median (y) | 38 |
| Range | 31-55 |
| Sex | |
| Male | 36 |
| Female | 12 |
| Disease duration before cladribine | |
| Median (mo) | 15 |
| Range | 0-668 |
| Treatment before cladribine | |
| None | 29 |
| Splenectomy alone | 3 |
| Interferon alone | 6 |
| Splenectomy, interferon | 6 |
| Splenectomy, interferon, 2′-deoxycoformycin | 2 |
| Chlorambucil, splenectomy | 1 |
| Other regimens | 1 |
| First response to cladribine | |
| CR | 37 |
| PR | 8 |
| Unknown | 3 |
| Peripheral blood hematologic parameters at first relapse | |
| Absolute neutrophil count (×109/L) | |
| Median (range) | 1.4 (0.6-6.0) |
| Hemoglobin level (g/dL) | |
| Median (range) | 14.2 (8.7-17.5) |
| Platelets (×109/L) | |
| Median (range) | 135 (4-403) |
| Duration to first relapse from cladribine therapy | |
| Median (mo) | 54 |
| Range | 7-246 |
| Treatment at relapse | |
| None | 11 |
| Cladribine | 31 |
| Rituximab | 5 |
| Cladribine + rituximab | 1 |
| Response to second course of cladribine (31 patients) | |
| CR | 12 |
| PR | 6 |
| CHR | 8 |
| No response | 1 |
| Unknown | 4 |